CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 674 enrolled
Drug / intervention
Ertapenem +5 moredrug
Likely dose
Not stated in record
Key inclusion· 6
  • Age ≥18 years
  • Intra-operative or post-operative enrollment with visual confirmation of pus and peritonitis from cholecystitis rupture, diverticular perforation, appendiceal perforation, traumatic bowel perforation (>12 hours post-injury), secondary peritonitis, or intra-abdominal abscess with intraperitoneal involvement
  • OR pre-operative enrollment with open laparotomy, percutaneous abscess drainage, or laparoscopic surgery planned within 24 hours before first study drug dose
  • At least one systemic inflammatory indicator: fever >38°C, hypothermia <35°C, WBC >12,000/mm³, SBP <90 mmHg without vasopressors, tachycardia >90 bpm AND tachypnea >20 breaths/min, or hypoxia ≤90% on room air
Key exclusion· 21
  • Traumatic bowel perforation with surgery <12 hours post-injury; gastroduodenal ulcer perforation with surgery <24 hours; or non-infectious primary intra-abdominal processes
  • Abdominal wall abscess, bowel obstruction without perforation, or ischemic bowel without perforation
  • Simple cholecystitis, gangrenous cholecystitis without rupture, simple appendicitis, acute suppurative cholangitis, infected necrotizing pancreatitis, or pancreatic abscess
  • Surgery included staged abdominal repair, open abdomen technique, or marsupialization

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03358576
NCT03358576Phase 3Completed

Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efiicacy, Tolerability & Safety of Sulopenem & Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro-metronidazole for Treatment of cIAI in Adults

Iterum Therapeutics, International Limited·interventional·Posted Nov 30, 2017·Updated Dec 1, 2020

In Brief

A Phase 3 clinical trial evaluating Ertapenem, Sulopenem-Etzadroxil/Probenecid, and 4 other interventions for Intra Abdominal Infections. Completed, enrolled 674 participants across 42 sites in 7 countries.

Detailed Summary

This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability and safety of sulopenem followed by sulopenem-etzadroxil/probenecid versus ertapenem followed by ciprofloxacin-metronidazole for treatment of complicated intra-abdominal infections in adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Estonia, Georgia, Hungary, Latvia, Poland, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 30, 2017
Enrollment StartSep 18, 2018
Primary CompletionOct 2, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.6 years ago

Interventions

Ertapenemdrug

Antibiotic for complicated intra-abdominal infection

Sulopenem-Etzadroxil/Probeneciddrug

Antibiotic for complicated intra-abdominal infection

Ciprofloxacindrug

Antibiotic for complicated intra-abdominal infection

Metronidazoledrug

Antibiotic for complicated intra-abdominal infection

Amoxicillin-Clavulanatedrug

Antibiotic for complicated intra-abdominal infection

Sulopenemdrug

Antibiotic for complicated intra-abdominal infection